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Objectives. This prospective study investigated the behavior of 
thrombin generation and activity during thrombolysis and con- 
comitant heparin administration. 
Background. It has been shown that during thrombolytic 
therapy there is an increase in thrombin generation and activity. 
Increased thrombin activity is suppressed by concomitant intra- 
venous heparin, but it is unknown whether thrombin generation is 
also affected. 
Methods. Thrombin generation was assessed by measuring 
prothrombin fragment 1 + 2 and thrombin-antithrombin com- 
plex plasma levels and thrombin activity by measuring fibrinopep. 
tide A plasma levels. Serial blood samples were obtained before 
and at 90 rain and 24 and 48 h after the administration of 
streptokinase (15 patients), recombinant tissue-type plasminogen 
activator (15 patients) or anistreplase (13 patients). An intrave- 
nous bolus of heparin (5,000 IU) was administered before the 
start of thrombolytic therapy, followed by an infusion of 1,000 U/h 
to maintain an activated partial thromboplastin time >1.5 times 
baseline. 
Results. During thrombolytic and concomitant heparin ther- 
apy, there was an increase in the plasma levels of prothrombin 
fragment 1 + 2 (baseline 1.08 vs. 2.73 nmol/liter, p < 0.001) and 
thrombin-antithrombin complex (baseline 6.5 vs. 17.1 pg/mi, p < 
0.01) at 90 rain, whereas no change was observed in fibrinopeptide 
A at 90 min (baseline 2.8 vs. 3.0 nmol/liter, p = NS). 
Conclusions. During thrombolytic therapy with both fibrin- 
specific and non-fibrin-specific drugs, there is an increase in 
thrombin generation despite concomitant administration of intra- 
venous heparin. 
(J Am CoU Cardiol 1995;25:203-9) 
Failure to achieve reperfusion and the occurrence of subse- 
quent reocclusion after successful thrombolysis are major 
limitations of thrombolytic therapy in acute myocardial infarc- 
tion. Recent biochemical evidence has shown that thrombo- 
lytic agents activate both platelets (1,2) and clotting factors 
(3-8). The activation of the hemostatic system is considered to 
play a pivotal role in preventing or retarding fibrinolytic- 
induced coronary reperfusion and in producing early reocclu- 
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sion, and this has led to the recommendation f adjunctive 
antithrombotic therapy with aspirin and heparin (9). The 
clinical benefit of the addition of aspirin to thrombolysis has 
already been demonstrated (10); the clinical benefit of the 
addition of heparin to thrombolysis is still controversial 
(11,12). 
Thrombin plays a central role in the pathogenesis of 
coronary artery thrombosis and rethrombosis. It is a serine 
protease generated by factor Xa activity through the cleavage 
from prothrombin of a 32-amino acid fragment, called pro- 
thrombin fragment 1 + 2. Free thrombin is inactivated by 
antithrombin as soon as it is generated, and the thrombin- 
antithrombin complex is cleared. If the generation of thrombin 
is such that it overwhelms this natural anticoagulatory mech- 
anism, the thrombin cleavage of the 16-amino acid peptide 
fibrinopeptide A from fibrinogen initiates fibrin formation. 
The availability of specific immunoassays for measuring the 
plasma levels of prothrombin fragment 1 + 2 (13), thrombin- 
antithrombin complex (14) and fibrinopeptide A (15) allows 
thrombin generation and activity to be evaluated under in vivo 
conditions. Previous studies have shown that, during throm- 
bolysis with either recombinant tissue-type plasminogen acti- 
vator (rt-PA) or streptokinase (6-8), there is an increase in the 
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plasma levels of thrombin-antithrombin complex and fibrino- 
peptide A, and this increase can be suppressed by heparin (6). 
During rt-PA treatment, there is also an increase in prothrom- 
bin fragment 1 + 2 (5), but it is not yet known whether this can 
be prevented by heparin. Although eparin is very effective in 
inhibiting thrombin activity on fibrinogen (16), it seems to be 
less effective in inhibiting factor Xa activity on prothrombin, 
especially when factor Xa is incorporated in the tenase com- 
plex (17). 
In the present study we prospectively measured the plasma 
concentrations of prothrombin fragment 1 + 2, thrombin- 
antithrombin complex and fibrinopeptide A in patients with 
acute myocardial infarction who were receiving thrombolytic 
therapy in conjunction with heparin. The simultaneous mea- 
surement of these markers, which monitor different steps of 
the coagulation cascade, allowed different levels of activation 
of the hemostatic mechanism to be detected under in vivo 
conditions. 
Methods 
Between April 1990 and July 1991, 115 consecutive patients 
<70 years old admitted to the coronary care unit of the Second 
Division of Cardiology, Niguarda Hospital, Milan, with a 
diagnosis of myocardial infarction and no contraindications to 
thrombolytic therapy were considered eligible to enter the 
study. Inclusion criteria were 1) a history of chest pain lasting 
at least 30 min but no longer than 6 h that failed to respond to 
sublingual or intravenous nitrates; 2) ST segment elevation or 
depression ->0.2 mV in at least two contiguous electrocardio- 
graphic leads evolving into pathologic Q waves and ST-T wave 
changes; and 3) development of elevated creatinine kinase and 
MB fraction levels of at least twice the upper normal imit. 
Exclusion criteria were 1) concomitant peripheral vascular 
disorders or valvular heart disease (9 patients); 2) previous 
coronary artery bypass surgery or coronary angioplasty (5 
patients); 3) anticoagulant treatment before baseline blood 
sampling (40 patients); 4) comorbid conditions known to affect 
coagulation activation markers (malignancy, sepsis, nephritis, 
collagen disorders, coagulation disorders) (6 patients); and 5) 
difficult venous access (12 patients). 
Study design. This was a prospective study of consecutive 
patients. After determination f eligibility and inclusion into 
the study, a baseline blood sample was obtained from enrolled 
patients before any treatment was started. Subsequently, all 
patients received aspirin (165 to 325 mg) and an intravenous 
bolus of heparin (5,000 IU), immediately followed by a con- 
tinuous intravenous infusion of heparin (1,000 IU/h), which 
was then adjusted to maintain the activated partial thrombo- 
plastin time at >1.5 times baseline values. Thrombolytic 
therapy was started immediately after the administration f the 
heparin bolus. The patients were randomized to receive 1) 
rt-PA, 10 mg bolus followed by an additional 50 mg over the 
first hour and 40 mg over the next hour; 2) streptokinase, an 
infusion of 1,500,000 U over 1 h; 3) anistreplase, 30 U infused 
over 5 min. Additional treatments included intravenous beta- 
adrenergic blocking agents (5 mg of intravenous atenolol, then 
50 to 100 mg/day orally [12 patients]), nitrates (0.1 to 0.8 t~g/kg 
body weight per min for 48 h [30 patients]), angiotensin- 
converting enzyme inhibitors (5 to 10 mg/day of oral lisinopril 
[6 patients]). Additional blood samples for coagulation activa- 
tion markers were obtained 90 min and 24 and 48 h after the 
start of thrombolytic therapy. 
Blood sampling and processing. Venipunctures were per- 
formed atraumatically b three specially trained investigators 
(P.A.M., L.O., A.S.) using 19-gauge butterfly infusion sets and 
the two-syringe technique. Samples at different imes were 
obtained by separate venipunctures, and inadequate samples 
were prospectively discarded. Because all of our blood samples 
were obtained by means of clean venipunctures and meticulous 
technique to minimize in vitro artifacts, the values of the 
coagulation activation markers are much lower than those 
reported in other studies (3,6) during which the blood samples 
were obtained using indwelling catheters. 
After the first 4 ml of blood was discarded, samples were 
collected directly into refrigerated vacutainers containing an 
anticoagulant mixture composed of a thrombin inhibitor, eth- 
ylenediaminetetraacetic acid (EDTA) and aprotinin purchased 
from Byk-Sangtec (Dietzenbach, Germany). The ratio of anti- 
coagulant to blood was 1:9 (vol/vol). Blood samples were 
immediately centrifuged at 2,500 g for 25 min at 4°C; the 
platelet-free plasmas were frozen on dry ice and stored at 
-80°C until analyzed. 
Biochemical determinations. All samples were analyzed by 
investigators who were not aware of the clinical data. Plasma 
levels of prothrombin fragment 1 + 2 were measured using 
double-antibody radioimmunoassay as previously described 
(18). This method has an interassay coefficient of variation of 
-8%. The plasma levels of thrombin-antithrombin complex 
were measured using a commercially available kit (Enzygnost 
TAT kit, Beringwerke AG, Marburg, Germany). The coeffi- 
cient of variation of this method is -6%. The plasma concen- 
trations of fibrinopeptide A were determined in duplicate by 
means of enzyme immunoassay in plasma extracted twice with 
bentonite to remove fibrinogen (Diagnostica Stago, Asnieres, 
France). This technique has an interassay coefficient of varia- 
tion of -5%. 
Informed consent. The study was approved by the Institu- 
tional Review Board of the Ca' Granda Niguarda Hospital, 
and informed consent was obtained from all subjects. All of the 
clinical studies and informed consent procedures were also 
approved by the Committee on Clinical Investigations of the 
Beth Israel Hospital. 
Statistical analysis. The deviations from a normal distri- 
bution of plasma concentrations of prothrombin fragment 
1 + 2, thrombin-antithrombin complex and fibrinopeptide A
were tested by calculating the coefficients of skewness and 
kurtosis. Because the plasma levels of coagulation activation 
markers were found to be non-normally distributed, paired 
data were analyzed by means of the Wilcoxon signed-rank test 
or, for multiple comparisons, by the Friedman test. Kruskal- 
Wallis one-way analysis of variance was used to test the 
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Table 1. Clinical Characteristics of the Study Patients 
rt-PA Streptokinase Anistreplase 
(n - 15) (n : 15) (n : 13) 
Age (yr) 63 = 8 57 + 7 58 _+ 7 
Male gender 12 (80) 13 (86) 12 (80) 
Smokers 10 (66) 11 (73) 11 (73) 
Hypertension 3 (29) 2 (13) 1 (6) 
Diabetes mellitus 1 (6) 2 (13) 1 (6) 
Cholesterol (mg/dl) 220 _+ 24 207 _+ 22 227 + 39 
Data presented are mean value _+ SD or number (%) of patients, rt-PA - 
recombinant tissue-type plasminogen activator. 
difference between groups; subsequent pairwise comparisons 
were made using the Mann-Whitney U test. Descriptive statis- 
tics include mean values and standard eviations or medians, 
25th and 75th and 10th and 90th percentiles as appropriate. All 
presented tests are two-tailed; pvalues <0.05 were regarded as 
statistically significant. The number of patients who exhibited 
prothrombin fragment 1 + 2 and fibrinopeptide A plasma 
concentrations of above the upper normal limit was calculated 
by determining the 95th percentile of the distribution in a 
control group of 32 healthy subjects matched for age and 
gender with the study patients, which was set at 1.02 nmol/liter 
for prothrombin fragment 1 + 2, 4 /~g/liter for thrombin- 
antithrombin complex and 2.2 nmol/liter for fibrinopeptide A. 
Resu l ts  
Serial blood samples were taken from 43 patients (37 men, 
6 women; mean [_+SD] age 58 _+ 7 years). Twenty patients had 
an infarction of the anterior wall, 15 of the inferior wall and 8 
of the posterior wall. The mean time between the onset of 
symptoms and the start of thrombolytic therapy was 3.5 _+ 
1.5 h. Fifteen patients received rt-PA, 15 patients streptokinase 
and 13 patients anistreplase. No significant difference was 
observed in clinical characteristics of the three treatment 
groups (Table 1). 
Prothrombin fragment 1 + 2, thrombin-antithrombin 
complex and fibrinopeptide A plasma levels at different ime 
points in the 43 study patients. Figure 1 shows medians and 
25th, 75th, 10th and 90th percentiles ofprothrombin fragment 
1 + 2, thrombin-antithrombin complex and fibrinopeptide A
plasma levels before and after thrombolytic therapy. There was 
a significant change in prothrombin fragment 1 + 2 plasma 
concentrations at the different time points (p < 0.0001). From 
a baseline level of 1.08 nmol/liter (interquartile range 0.71 to 
1.66), prothrombin fragment 1 + 2 plasma levels increased to 
2.73 nmol/liter (interquartile range 2.0 to 3.48) 90 min after the 
start of thrombolytic therapy (p < 0.001). No difference in 
comparison with baseline was observed after 24 h (1.03 nmol/ 
liter, interquartile range 0.69 to 1.35, p = 0.8) or 48 h 
(1.08 nmol/liter, interquartile range 0.8 to 1.57, p = 0.7). 
Abnormal values of prothrombin fragment 1 + 2 were found in 
31 (72%) of the 43 patients at baseline, 40 (93%) of 43 at 
90 rain, 22 (53%) of 41 at 24 h and 21 (60%) of 35 at 48 h. 
There was a significant change in thrombin-antithrombin 
complex plasma concentrations at the different ime points 
(p < 0.001). From a baseline of 6.5 t~g/liter (interquartile range 
5.2 to 10.3), thrombin-antithrombin complex plasma levels 
increased to 17.1 /zg/liter (interquartile range 12.5 to 26.6) 
90 rain after the start of thrombolytic therapy (p < 0.01). No 
difference in comparison with baseline was observed after 24 h 
(7.1 /~g/liter, interquartile range 3.9 to 13.3, p = 0.6) or 48 h 
(5.8/zg/liter, interquartile range 3.8 to 7.7, p = 0.1). Abnormal 
values of thrombin-antithrombin complex were found in 33 
(76%) of the 43 patients at baseline, 40 (93%) of 43 at 90 min, 
22 (53%) of 41 at 24 h and 16 (46%) of 35 at 48 h. 
There was a significant decrease in fibrinopeptide A plasma 
concentrations at the different ime points (p < 0.01). Fibrin- 
opeptide A plasma levels were 2.8 nmol/liter (interquartile 
range 1.3 to 4.1) at baseline and 3.0 nmol/liter (interquartile 
range 1.45 to 4.5) 90 min after the start of thrombolytic therapy 
(p = 0.8). In comparison with baseline there was a trend 
toward a decrease in fibrinopeptide A plasma levels after 24 h 
(1.8 nmol/liter, interquartile range 1.3 to 2.8, p = 0.051) and 
48 h (2.0 nmol/liter, interquartile range 1.1 to 2.5, p = 0.019). 
Abnormal values of fibrinopeptide A were found in 25 (59%) 
of the 43 patients at baseline, 25 (59%) of 43 at 90 min, 19 
(46%) of 41 at 24 h and in 16 (46%) of 35 at 48 h. 
Prothrombin fragment 1 + 2, thrombin-antithrombin 
complex and fibrinopeptide A plasma levels according to the 
thrombolytic drug administered. Figure 1 shows individual 
values of prothrombin fragment 1 + 2, thrombin-antithrombin 
complex and fibrinopeptide A plasma levels before and after 
thrombolytic therapy according to the thrombolytic drug ad- 
ministered. Median prothrombin fragment l + 2, thrombin- 
antithrombin complex and fibrinopeptide A plasma levels, as 
well as their interquartile ranges as functions of the thrombo- 
lytic drug administered at different times are given in Table 2. 
There were no significant differences in the baseline plasma 
levels of the coagulation activation markers among the three 
treatment groups. Whichever thrombolytic drug was given, in 
comparison with baseline, at 90 min there was a significant 
increase in prothrombin fragment 1 + 2 (p < 0.01) and 
thrombin-antithrombin complex plasma levels (p < 0.0l), 
whereas no significant change in fibrinopeptide A plasma 
levels was observed. Prothrombin fragment l + 2 and throm- 
bin-antithrombin complex plasma levels at the 24- and 48-h 
determinations were not significantly different in comparison 
with baseline, whereas the 48-h plasma levels of fibrinopeptide A 
were significantly lower than baseline values in all three 
treatment groups (p < 0.05). 
No differences were detected among the three groups in 
terms of median changes in prothrombin fragment 1 + 2 at 
different imes. At 90 rain there was a median increase of 
1.45 nmol/liter (interquartile range 0.58 to 3.02) in the rt-PA 
group, 1.67 nmol/liter (interquartile range 0.88 to 2.65) in the 
streptokinase group and 1.77 nmol/liter (interquartile range 
-16 to 2.79) in the anistreplase group (p = 0.95). Compared 
with baseline, at 24 h there was a median change of 
0.02 nmol/liter (interquartile range -0.29 to 0.44) in the rt-PA 
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Figure 1. Plots of prothrombin fragment 1 + 2 
(top), thrombin-antithrombin complex (middle) 
and fibrinopeptide A (bottom) plasma levels in 
43 patients with acute myocardial infarction who 
received intravenous heparin in addition to 
thrombolytic therapy with recombinant tissue- 
type plasminogen activator (e), streptokinase 
(0) or anistreplase (Y). Samples were obtained 
at hospital admission (baseline) and 90 min, 24 h 
and 48 h after the start of thrombolytic therapy. 
Plot boxes with median values and 25th, 75th, 
10th and 90th percentiles refer to the whole 
study group. *p < 0.001, ~p < 0.01, §p < 0.05 
versus baseline. 
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group, -0.13 nmol/liter (interquartile range -0.26 to 0.75) in 
the streptokinase group and -0.39 nmol/liter (interquartile 
range -1.08 to 0.46) in the anistreplase group (p = 0.58). At 
48 h there was a median change of 0.19 nmol/liter (interquar- 
tile range 0.17 to 0.35) in the rt-PA group, -0.08 nmol/liter 
(interquartile range -0.42 to -0.07) in the streptokinase 
group and 0.13 nmol/liter (interquartile range -0.64 to 1.01) in 
the anistreplase group (p = 0.56). 
No differences were detected among the three groups in 
terms of median changes in thrombin-antithrombin complex 
at different time points. At 90 min there was a median increase 
of 10.1 /xg/liter (interquartile range 2.4 to 14.8) in the rt-PA 
group, 5.6 /zg/liter (interquartile range 5 to 17.9) in the 
streptokinase group and 9.4/zg/liter (interquartile range 0.55 
to 19.2) in the anistreplase group (p = 0.94). Compared with 
baseline, at 24 h there was a median change of -0.5/zg/liter 
(interquartile range -4.8 to 1.8) in the rt-PA group, 
2.7/xg/liter (interquartile range -5  to 13.6) in the streptoki- 
nase group and -1.6 t~g/liter (interquartile range -21 to 4.45) 
in the anistreplase group (p = 0.24). At 48 h there was a 
median change of -1.15/~g/liter (interquartile range -2.5 to 
1.5) in the rt-PA group, 1.7/~g/ml (interquartile range -6.8 to 
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Table 2. Plasma Concentrations of Prothrombin Fragment 1+ 2, Thrombin-Antithrombin Complex and Fibrinopeptide A According to the 
Different Thrombolytic Drugs Administered 
Prothrombin Fragment 1 + 2 (nmoHiter) Thrombin-Antithrombin Complex (~tg/liter) Fibrinopeptide A (nmol/liter) 
rt-PA Streptokinase Anistreplase rt-PA Streptokinase Anistreplase rt-PA Streptokinase Anistreplase 
(n : 15) (n = 15) (n = 13) (n = 15) (n : 15) (n = 13) (n - 15) (n = 15) (n : 13) 
Baseline 1.26 l.t 1 1.08 6.4 6.2 8.6 2.8 2.7 4.1 
(0.79-2.06) (0.71-1.44) (0.7-1.88) (5.6-9) (4.5-8.8) (6-17.8) (1.6-4.1) (0.9-2.8) (1.3-8.8) 
90 rain 3.13' 2.57* 2.99* 16.8" 16.4' 24.5* 2.5 2.5 4.5 
(2.42-3.95) (2.06-3.13) (1.6-4.18) (13.7-20.2) (10.9-20.5) (15.8-33.5) (1.4-4.2) (1.4-4) (2-6) 
24 h 0.95 1.05 1.03 4.2 10.8 10 1.3t 1.85 2.3 
(0.83-1.82) (0.59-1.41) (0.65-1.12) (3.5-6) (5.8-17.4) (3.4-14.9) (0.8-1.7) (1.1-3) (1.5-5) 
48 h 1.06 0.94 1.28 5.7 4.8 7.6 1.37 1.1t 2.4? 
(0.77-1.82) (0.81-1.23) (1.01-1.84) (3.5-7.7) (4.1-6.5) (4-16.7) (1.0-2.2) (0.8-2.2) (2.3-3.1) 
*p < 0.01 versus baseline and 24 and 48 h. qp < 0.05 versus baseline. Data presented are median values (25th to 75th percentile). 
2.7) in the streptokinase group and - 1.2/zg/liter (interquartile 
range -3.55 to 0.35) in the anistreplase group (p = 0.57). 
No differences were detected among the three groups in 
terms of median changes in fibrinopeptide A at different ime 
points. At 90 rain there was a median change of 1.1 nmol/liter 
(interquartile range 0 to 3.8) in the rt-PA group, 0.9 nmol/liter 
(interquartile range -0.35 to 2.5) in the streptokinase group 
and 0.8 nmol/liter (interquartile range -4.8 to 1.3) in the 
anistreplase group (p = 0.25). Compared with baseline, at 24 h 
there was a median change of -1.35 nmol/liter (interquartile 
range -2  to -0.1) in the rt-PA group, 0 nmol/liter (interquar- 
tile range -1.05 to 0.35) in the streptokinase group and 
0.1 nmol/liter (interquartile range -2.55 to 0.85) in the anis- 
treplase group (p = 0.42). At 48 h there was a median change 
of -0.7 nmol/liter (interquartile range -1 to 0.1) in the rt-PA 
group, -0.2 nmol/liter (interquartile range -1.9 to 0.9) in the 
streptokinase group and -1.2 nmol/liter (interquartile range 
-3.55 to 0.35) in the anistreplase group (p = 0.66). 
Discuss ion 
Thrombin generation and activity during thrombolysis. In 
the present study the plasma levels of prothrombin fragment 
1 + 2 and thrombin-antithrombin complex (indexes of throm- 
bin generation by factor Xa activity) and fibrinopeptide A (an 
index of thrombin activity on fibrinogen) were measured at 
different imes in patients with myocardial infarction receiving 
different hrombolytic drugs in conjunction with heparin. The 
data show that during thrombolytic therapy and concomitant 
intravenous heparin, thrombin activity is efficiently inhibited, 
but there is an increase in thrombin generation. Thrombin 
generation increased 90 min after thrombolytic therapy and 
was similar to baseline after 24 and 48 h, whereas thrombin 
activity showed no change at 90 rain and decreased after 24 and 
48 h. Previous tudies have shown that there is an increase in 
thrombin activity in patients receiving thrombolytic therapy 
(3-8) that does not occur when heparin is given before and 
during treatment (6). In a pilot study (19), we also observed a 
marked increase in both thrombin generation and activity in 
patients receiving thrombolytic therapy with rt-PA or strep- 
tokinase in the absence of concomitant anticoagulation with 
heparin. Therefore, we designed the present study to evaluate 
the behavior of coagulation system markers in patients receiv- 
ing thrombolytic therapy and concomitant heparin treatment. 
The data show that there is no significant increase in 
fibrinopeptide A in patients receiving heparin before throm- 
bolytic therapy. Thus, despite experimental evidence that 
clot-bound thrombin is protected from inactivation by anti- 
thrombin III-dependent anticoagulants (20), in vivo biochem- 
ical data seem to suggest that during thrombolytic therapy, the 
contribution of clot-bound thrombin to the increase in fibrin- 
opeptide A plasma levels is minor and that intravenous 
heparin is effective in preventing an increase in thrombin 
activity in most patients. A previous tudy (5) has shown that 
thrombin generation is increased during rt-PA infusion in 
patients not receiving heparin. Our data show that heparin is 
not effective in inhibiting an increase in thrombin generation i
patients receiving thrombolytic therapy. An in vitro study (17) 
on human whole blood has shown that factor Xa binding to 
activated platelets leads to protection against inactivation by 
the heparin-antithrombin III complex, and the degree of 
protection is closely related to the extent of prothrombin 
activation. 
It is possible to speculate that at high rates of in vivo 
thrombin generation, as observed in patients with acute myo- 
cardial infarction, asignificant amount of factor Xa is bound to 
activated platelets, thus allowing this serine protease to resist 
the action of heparin. In addition, the direct activation of 
platelets (1,2) and factor Va (21) during thrombolysis, as well 
as the reexposure of the ruptured plaque to blood flow, might 
lead to the generation of more factor Xa and, consequently, to 
thrombin generation. The increase in prothrombin fragment 
1 + 2 and thrombin-antithrombin complex plasma levels in the 
first hours after the initiation of thrombolysis despite heparin 
treatment further supports this hypothesis. 
Thrombin generation and activity according to the throm- 
bolytic drug administered. The changes in the measured 
coagulation activation markers were similar regardless of the 
thrombolytic drug used. Although previous in vitro studies 
(22,23) have suggested that the effects of fibrin-specific or 
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non-fibrin-specific thrombolytic agents on the activation of 
hemostatic mechanisms may be different, clinical studies have 
found a similar early increase in coagulation activation mark- 
ers. Owen et al. (4) have shown that patients receiving heparin 
in association with streptokinase or rt-PA presented a similar 
increase in plasma fibrinopeptide A levels and concluded that 
this transient elevation was a result of transient hrombin 
activity and that the close similarity in the observed increases 
in patients receiving streptokinase or rt-PA indicates that this 
relates more to the thrombolysis tself than to the individual 
thrombolytic agent. Gulba et al. (24), who prospectively stud- 
ied thrombin-antithrombin complex plasma levels in patients 
who received rt-PA or pro-urokinase after heparin treatment 
and then underwent angiography 90 min and 24 to 36 h after 
thrombolytic therapy, did not detect any significant differences 
between the effects of the two thrombolytic regimens. 
Limitations of the study. One possible limitation of the 
present study concerns the use of plasma fibrinopeptide A
levels as a marker of local coronary thrombin activity. Only a 
percent of patients with acute myocardial infarction show 
elevated fibrinopeptide A levels. Furthermore, levated levels 
have been found in patients with both thrombotic and inflam- 
matory disorders of various types, thereby limiting the diag- 
nostic specificity of the assay. However, our study was not 
aimed at assessing a link with coronary thrombosis or its 
evolution and coagulation activation markers but at monitor- 
ing the time course of thrombin generation and activity during 
thrombolysis and concomitant heparin administration. 
Another possible limitation concerns the high degree of 
variability of the coagulation system markers, which limits the 
power of the study to detect significant increases in fibrinopep- 
tide A during thrombolysis or different behaviors among three 
thrombolytic regimens. The primary aim of the study was to 
assess hemostatic system activation in patients with acute 
myocardial infarction receiving thrombolytic therapy in con- 
junction with heparin and not to make a direct comparison of 
specific treatments. However, with an alpha error of 0.05 and 
a beta of 0.1, our sample size allows the detection of a 
difference between the most and the least activating agents of 
18% for prothrombin fragment 1 + 2, 43% for thrombin- 
antithrombin complex and 40% for fibrinopeptide A. 
Conclusions. The finding of increased thrombin genera- 
tion during thrombolysis despite the concomitant administra- 
tion of heparin raises a number of questions. Apart from 
catalyzing the conversion of fibrinogen to fibrin, thrombin is a 
potent activator of a variety of cell events, such as platelet 
aggregation (25), secretion and formation of thromboxane A 2 
(26), contraction ofsmooth muscle cells (27,28) and expression 
of tissue factor on endothelial cells (29), all of which may have 
detrimental effects at the site of highly unstable postthrom- 
bolysis residual lesions (30,31). It is tempting to speculate that 
the remarkably favorable ffects of direct antithrombin agents 
compared with heparin (32) during thrombolysis may be 
attributable to a more extensive inhibition of blood coagula- 
tion, which includes both fibrin formation and platelet aggre- 
gation. In the setting of coronary thrombolysis, thrombin is the 
main factor responsible for platelet activation; therefore, the 
favorable results obtained with aspirin (10), which only inhibits 
the thromboxane-induced platelet aggregation, might be fur- 
ther improved by direct hrombin inhibition. 
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